The nation’s pharmaceutical lobby is vigorously opposing legislation before the D.C. Council intended to regulate drug-sales reps and the unapproved use of prescription medicine, claiming it will unnecessarily interfere in the relationship between doctors and patients.

For at least the second time in three years, the Pharmaceutical Research and Manufacturers Association is butting heads with Council Member David Catania over a major drug reform bill.